You could apply same arguments to your Resonance Health.... uptake of technology is excruciatingly slow and glacial...
With microcaps I would rather stick with "ticket-clipping" business models before getting into brand ownership. Ticket clipping leverages you into the upside at zero cost if the licensee expands business.
What we do know:
* ramp up has been slow, not due to demand but due to supply
* the company has been provided a sales/revenue plan out to 2021
* P&G has/is expanding Magnemask from China/Taiwan/Phillipines/USA/Australia. Thats expansion, not contraction.
* P&G have signed up to a second technology thats being consumer tested. Thats expansion not contraction of interest
* P&G have given back other technologies. No great surprise as P&G is made up of silos and our technology might interest some but not all stakeholders.
As for the non-ticket clipping business, what we do know is:
* stakeholders werent interested in BodyGuard until a commercial ready product was available. That became available in November 2017
* a UK company is funding and running a consumer and efficacy trial right now - something that didnt happen when you held I presume.
* a second trial of Surface Hygiene is occurring.
Salty Stale Bulls might call it continued carrot dangling, I call it things that are very much still in play...
- Forums
- ASX - By Stock
- WFL
- Encouraging Report
Encouraging Report, page-68
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable